Elevance Health announces 2027 plans: what it means for Elevance Health stock

Published on 10/07/2026 at 14:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 49.83 billion and adjusted EPS USD 7.45. Elevance Health stock costs EUR 355.25 on October 7, 2026 versus EUR 354.75.

Draufsicht-Arrangement mit Aktienzertifikat, ISIN-Karte US2855211023 und Stethoskop — Elevance Health US2855211023 Flatlay mit Aktienzertifikat ISIN-Karte Stethoskop und medizinischen Utensilien auf Marmor, Illustration mit AI erstellt.

Elevance Health (ISIN US0367521038) was trading at EUR 355.25 at Lang & Schwarz on October 7, 2026 at 2:42 p.m. CEST, up 0.14 percent versus the prior close of EUR 354.75. The insurer announced affiliated 2027 Medicare Advantage plans on October 1, while third-quarter results are scheduled for October 21, 2026.

2027 plans expand benefit coordination

As Yahoo Finance reported on October 1, 2026, Elevance Health said its affiliated plans would offer 2027 Medicare Advantage coverage with expanded support for chronic conditions and dual-eligible members.

The announcement includes plans that combine covered everyday benefits through a single prepaid card. Medicare's annual enrollment period runs from October 15 through December 7, 2026, for coverage beginning January 1, 2027.

Quarterly figures set the earnings base

According to MarketBeat on October 6, 2026, Elevance Health reported USD 49.83 billion of revenue and adjusted earnings per share of USD 7.45 for the second quarter of 2026. Adjusted earnings per share exceeded the USD 6.21 consensus by USD 1.24, while revenue topped the USD 48.88 billion consensus by USD 0.95 billion.

That comparison gives the October 21 reporting date greater importance: the company will need to show whether the second-quarter earnings advantage carries into the third quarter. MarketBeat listed 15 Buy ratings and eight Hold ratings among 23 analysts, with an average 12-month target of USD 440.90 on October 6, 2026.

Stock remains below its yearly high

Elevance Health's market capitalization was USD 86.8 billion as of October 6, 2026. The NYSE-listed stock's 52-week range was USD 274.84 to USD 436.24, placing the latest US quote below its yearly high while the euro reference price remained tied to Lang & Schwarz.

At Lang & Schwarz, Elevance Health was trading at EUR 355.25 on October 7, 2026 at 2:42 p.m. CEST, plus 0.14 percent versus the Lang & Schwarz prior close of EUR 354.75. The further course of trading is shown by the continuously updated real-time quote of Elevance Health stock.